

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : A61K 9/00, 9/20</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 97/24109</b> (43) International Publication Date: 10 July 1997 (10.07.97)</p>
<p>(21) International Application Number: PCT/EP96/05884 (22) International Filing Date: 20 December 1996 (20.12.96) (30) Priority Data: 95203649.9 27 December 1995 (27.12.95) EP (34) Countries for which the regional or international application was filed: DE et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventor; and (75) Inventor/Applicant (for US only): GILIS, Paul, Marie, Victor [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).</p>	<p>(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published With international search report.</p>	
<p>(54) Title: BIOADHESIVE SOLID DOSAGE FORM</p> <p>(57) Abstract</p> <p>The present invention is concerned with bioadhesive pharmaceutical compositions comprising a pharmaceutically effective amount of an active ingredient, from 80 % to 98.8 % (w/w) pre-gelatinized starch, and from 1 % to 10 % (w/w) of a hydrophilic matrix forming polymer, <u>characterized in that</u> the composition further comprises from 0.2 % to 5 % (w/w) alkali C<sub>16-22</sub>alkyl fumarate as a lubricant; solid dosage forms such as tablets which are suitable for oral, nasal, rectal and vaginal administration; processes of preparing the compositions and solid dosage forms.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

## BIOADHESIVE SOLID DOSAGE FORM

---

5 The present invention is concerned with bioadhesive compositions and solid dosage forms prepared therefrom which have a regular and prolonged release pattern for a locally acting ingredient or also for a systemically acting drug, and which are suitable for oral, nasal, rectal and vaginal administration.

10 Known bioadhesive solid dosage forms are described, for example, in GB-2,042,888 (Teijin). Those dosage forms comprise an active ingredient, 50 to 95 % of a cellulose ether and 50 to 5 % of a high molecular weight crosslinked polyacrylic acid (carboxyvinyl polymer, carbomer, carbopol). Commercially available bioadhesive dosage forms are often double-layered (multi-layered) preparations with one adhesive layer and at least one non-adhesive layer (e.g. Teijin's Aftach<sup>®</sup>, Triamcinolone  
15 Acetonide Plastering Tablet).

An improved bioadhesive solid dosage form comprising a mixture of 5 % polyacrylic acid (Carbopol 934) with pregelatinized starch (drum-dried waxy maize) was described in EP-0,451,433 and in Eur. J. Clin. Pharmacol. (1992) 43: 137-140. Its main  
20 advantages were excellent bioadhesion and the total absence of tissue irritation. The development of a buccal tablet on an industrial scale using these disclosures proved unfeasible because of the impossibility to obtain industrially meaningful quantities of the lubricant sodium benzoate in micronized form (i.e. with a very high specific surface). All attempts to prepare buccal tablets with a non-micronized lubricant or  
25 without a lubricant failed. The lubricant proved to be essential in order to compress tablets from a granulate. Without it, the tablets stuck to the punches and dies used. A non-micronized lubricant then had the drawback that it needed to be used in unacceptably high amounts and that as a result thereof it affected such properties as bioavailability, release characteristics, taste and mouthfeel.

30 Consequently, a different lubricant having acceptable properties was called for. First, it was found that the two problems of taste and mouthfeel could be dealt with by restricting the lubricant used to a water-soluble lubricant. Poorly water-soluble lubricants such as magnesium stearate in combination with the bioadhesive carrier left  
35 a soap-like taste in the mouth. All of the problems could be solved satisfactorily by using a water-soluble alkali C<sub>16-22</sub>alkyl fumarate as lubricant, in particular sodium stearyl fumarate. A surprising finding was that the lubricant did not cause any loss of bioadhesion and did not negatively affect the release characteristics of the tablet. Upon

further upscaling of the wet granulation process used thus far for preparing tablets from the novel bioadhesive composition, yet another problem was encountered, namely disintegration of the granulate during its drying in e.g. a fluid bed drier. This problem has now been solved by dry compaction of some of the ingredients before compression.

5

The present invention relates to a bioadhesive pharmaceutical composition comprising a pharmaceutically effective amount of an active ingredient and from 80 % to 98.8 % (w/w) of a mixture of pre-gelatinized starch, from 1 % to 10 % (w/w) hydrophilic matrix forming polymer, characterized in that the composition further comprises from 10 0.2 % to 5 % (w/w) alkali C<sub>16-22</sub>alkyl fumarate as a lubricant.

Amounts of lubricants below 0.2 % cannot be considered effective, whereas their use in amounts in excess of 5 % do not further improve the process of compression into tablets, but on the contrary tend to impart undesired properties on the formulations. An 15 amount of about 2 % is considered optimal. Preferably, said lubricant is sodium stearyl fumarate which is commercially available in micronized form (Pruv®) and in addition is water-soluble and practically tasteless.

The amount of hydrophilic matrix forming polymer in the bioadhesive compositions according to the present invention in general ranges from 2.5 % to 7.5 % (w/w), and 20 most preferably is about 5 % (w/w). Examples of hydrophilic matrix forming polymers are polyacrylic acid (carbomer), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, polyvinyl alcohol and mixtures thereof. Polyacrylic acid and in particular carbomer 974P is useful in 25 ensuring that the dosage forms prepared from the bioadhesive compositions have a regular and prolonged release pattern of the active ingredient. Therefore it is the preferred hydrophilic matrix forming polymer in the bioadhesive compositions according to the present invention.

30 In order to prevent the abrasion of the granulate during the tablet compression, the composition according to the invention advantageously further comprises a glidant. An example of such a glidant is colloidal anhydrous silica. The amount of glidant can range from 0 % to about 1 % (w/w) and preferably is about 0.2 %.

35 A preferred composition according to the present invention comprises by weight based on the total weight of the composition :  
from 0.001 % to 10 % active ingredient ;  
from 80 % to 98.8 % pre-gelatinized starch;

from 1 to 10 % hydrophilic matrix forming polymer;  
 from 0.2 % to 5 % sodium stearyl fumarate ;  
 from 0 % to 1 % glidant.

- 5 Suitable active ingredients are those which exert a local physiological effect, as well as those which exert a systemic effect, either following penetrating the mucosa or - in the case of oral administration - following transport to the gastro-intestinal tract with saliva. The bioadhesive dosage forms prepared from the compositions according to the present invention are particularly suitable for active ingredients which exert their
- 10 activity during an extended period of time. Examples thereof are : analgesic and anti-inflammatory drugs (NSAIDs, acetyl salicylic acid, diclofenac sodium, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium, mefenamic acid, naproxen sodium, paracetamol, piroxicam, tolmetin sodium) ; anti-arrhythmic drugs (procainamide HCl, quinidine sulphate, verapamil HCl) ; antibacterial agents (amoxicillin, ampicillin,
- 15 benzathine penicillin, benzylpenicillin, cefaclor, cefadroxil, cephalixin, chloramphenicol, ciprofloxacin, clavulanic acid, clindamycin HCl, doxycycline HCl, erythromycin, flucloxacillin sodium, kanamycin sulphate, lincomycin HCl, minocycline HCl, nafcillin sodium, nalidixic acid, neomycin, norfloxacin, ofloxacin, oxacillin, phenoxymethyl-penicillin potassium); anti-coagulants (warfarin) ;
- 20 antidepressants (amitriptyline HCl, amoxapine, butriptyline HCl, clomipramine HCl, desipramine HCl, dothiepin HCl, doxepin HCl, fluoxetine, gepirone, imipramine, lithium carbonate, mianserin HCl, milnacipran, nortriptyline HCl, paroxetine HCl); anti-diabetic drugs (glibenclamide) ; antifungal agents (amphotericin, clotrimazole, econazole, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole,
- 25 miconazole nitrate, nystatin) ; antihistamines (astemizole, cinnarizine, cyproheptadine HCl, flunarizine, oxatomide, promethazine, terfenadine) ; anti-hypertensive drugs (captopril, enalapril, ketanserin, lisinopril, minoxidil, prazosin HCl, ramipril, reserpine) ; anti-muscarinic agents (atropine sulphate, hyoscine) ; antivirals (acyclovir, AZT, ddC, ddI, ganciclovir, loviride, tioripine, 3TC, delavirdine, indinavir, nelfinavir, ritonavir,
- 30 saquinavir) ; sedating agents (alprazolam, buspirone HCl, chlordiazepoxide HCl, chlorpromazine, clozapine, diazepam, flupenthixol HCl, fluphenazine, flurazepam, lorazepam, mazapertine, olanzapine, oxazepam, pimozone, pipamperone, piracetam, promazine, risperidone, selfotel, seroquel, sulpiride, temazepam, thiothixene, triazolam, trifluoperidol, ziprasidone) ; anti-stroke agents (lubeluzole, lubeluzole oxide, riluzole,
- 35 aptiganel, eliprodil, remacemide) ; anti-migraine drugs (alniditan, sumatriptan) ; beta-adrenoceptor blocking agents (atenolol, carvedilol, metoprolol, nebivolol, propranolol) ; cardiac inotropic agents (digitoxin, digoxin, milrinone) ; corticosteroids

- (beclomethasone dipropionate, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone) ; disinfectants (chlorhexidine) ; diuretics (acetazolamide, frusemide, hydrochlorothiazide, isosorbide) ; anti-Parkinsonian drugs (bromocryptine mesylate, levodopa, selegiline HCl) ;
- 5 enzymes ; essential oils (anethole, anise oil, caraway, cardamom, cassia oil, cineole, cinnamon oil, clove oil, coriander oil, dementholised mint oil, dill oil, eucalyptus oil, eugenol, ginger, lemon oil, mustard oil, neroli oil, nutmeg oil, orange oil, peppermint, sage, spearmint, terpineol, thyme) ; gastro-intestinal agents (cimetidine, cisapride, clebopride, diphenoxylate HCl, domperidone, famotidine, lansoprazole, loperamide
- 10 HCl, loperamide oxide, mesalazine, metoclopramide HCl, mosapride, olsalazine, omeprazole, ranitidine, rabeprazole, ridogrel, sulphasalazine) ; haemostatics (aminocaproic acid) ; lipid regulating agents (lovastatin, pravastatin, probucol, simvastatin) ; local anaesthetics (benzocaine, lignocaine) ; opioid analgesics (buprenorphine HCl, codeine, dextromoramide, dihydrocodeine) ;
- 15 parasympathomimetics (galanthamine, neostigmine, physostigmine, tacrine, donepezil, ENA 713 (exelon), xanomeline) ; vasodilators (amlodipine, buflomedil, amyl nitrite, diltiazem, dipyridamole, glyceryl trinitrate, isosorbide dinitrate, lidoflazine, molsidomine, nicardipine, nifedipine, oxpentifylline, pentaerythritol tetranitrate).
- 20 The compositions according to the present invention are best presented as dosage forms suitable for oral, nasal, rectal or vaginal administration. To that purpose they are shaped as a tablet, preferably with a surface area sufficient to ensure effective bioadhesion to mucosa. Flat, disc shaped tablets are particularly preferred.
- 25 For oral applications, several buccal tablets have been developed. In imitation of the miconazole tablet described in Eur. J. Clin. Pharmacol. (1992) 43: 137-140, a similar miconazole tablet using sodium stearyl fumarate was prepared, but -as described below- now on an industrial scale. Said tablet comprises by weight based on the total weight of the tablet :
- 30 10 % microfine miconazole nitrate ;  
82.8 % drum dried waxy maize starch ;  
2 % sodium stearyl fumarate ;  
5 % carbomer 974 P ; and  
0.2 % colloidal anhydrous silica.
- 35 In addition two tablets comprising respectively 1% and 5% of the active ingredient miconazole nitrate, and 91.8% and 87.8% drum dried waxy maize starch were prepared as well.

A buccal tablet comprising the triamcinolone (in imitation of Teijin's Aftach<sup>®</sup>) was also prepared. This tablet comprises by weight based on the total weight of the tablet

- 1 % microfine triamcinolone ;

5 91.8 % drum dried waxy maize starch ;

- 2 % sodium stearyl fumarate ;

- 5 % carbomer 974 P ; and

- 0.2 % colloidal anhydrous silica.

10 The compositions according to the present invention can be prepared on a small scale by a wet-granulation process comprising the steps of

- intimately mixing the active ingredient, the pre-gelatinized starch, and optionally the hydrophilic matrix forming polymer, until homogenous in a suitable mixer,

15 - wetting the thus obtained mixture with a pharmaceutically acceptable non-aqueous solvent,

- pressing the wet mixture through a sieve having a mesh width ranging from 1 to 1.8 mm ;

- drying the granulate ; and

20 - mixing the dried granulate with sodium stearyl fumarate and optionally the glidant.

In order to prepare tablets, the process is followed by the further step of

- compressing the granulate with lubricant and optional glidant, into tablets.

However, this process is not amenable to large-scale production because of the

25 disintegration of the granulate during the drying process in e.g. a fluid bed drier.

Tablets can be prepared, however, by a dry process comprising the steps of :

- intimately mixing the active ingredient, the pre-gelatinized starch and the hydrophilic matrix forming polymer in the dry state;

- compacting the thus obtained mixture into a sheet;

30 - breaking the sheet into a granules;

- sieving the granules ;

- blending the granulate with the lubricant and optionally the glidant; and

- compressing the blend into tablets.

35 In this process, the blending steps can conveniently be conducted in art-known planetary mixers. Similarly, the dry compaction is conveniently conducted in art-known compaction machines at a force in the range of 4 to 15 kN, preferably in the

range of 6 to 8 kN. The final compression step can be conducted at pressures ranging from 1500 to 3000 kg.cm<sup>2</sup>, in particular in the range of 1600 to 2000 kg.cm<sup>2</sup>.

The present invention is meant to extend to and include the products obtainable by the foregoing process.

The present invention also concerns the use of 0.2 % to 5 % (w/w) sodium stearyl fumarate as a lubricant and 80 % to 98.8 % (w/w) pre-gelatinized starch, 1 to 10 % hydrophilic matrix forming polymer for the manufacture of a bioadhesive dosage form.

The buccal tablets according to the present invention can be administered as follows. A tablet is placed on the gingiva, preferably in the region of the upper canines, and is fixed by gently pressing on the cheek for 1 minute. The tablet then is preferably moistened with the tongue to prevent sticking of the tablet to the cheek.

The gingiva seem to be the best site of application because of the long adhesion time (about 9 hours) and the slow clearance rate from the oral cavity.

#### Experimental Part

Example 1 : Miconazole nitrate 10 mg extended release buccal tablet.

Prior art formula (Eur. J. Clin. Pharmacol. (1992) 43: 137-140)

miconazole nitrate	10 mg
drum-dried waxy maize	82.8 mg
Carbopol 934	5 mg
silicon dioxide	0.2 mg
sodium benzoate	2 mg

The powders were blended for 10 min in a Turbula mixer and were directly compressed into tablets having a total weight of 100 mg.

#### Improved formula

miconazole nitrate (microfine)	10 mg
drum-dried waxy maize	82.8 mg
Carbopol 974 P	5 mg
colloidal anhydrous silica	0.2 mg
sodium stearyl fumarate	2 mg
ethyl alcohol *	q.s.



-7-

- \* ethyl alcohol is only used in the wet-granulation process of preparing tablets and does not appear in the end-product (approximately 0.1 g ethanol is used for every gram of the dry end formulation).

5 **Wet-granulation process (small scale)**

Miconazole nitrate, drum-dried waxy maize and Carbopol 974 P were mixed in a planetary mixer until homogenous and then wetted with ethyl alcohol. The dough-like paste was passed through a sieve (mesh openings of 1.8 mm) and allowed to dry at ambient temperature and pressure. When dried, the granulate was mixed with the  
10 colloidal anhydrous silica and the lubricant until homogenous. The granulate was then compressed into tablets having a total weight of 100 mg on a Korsch compression machine equipped with 6.5 mm flat punches.

**Dry compaction (industrial scale)**

15 One kg of miconazole nitrate (microfine), 8.28 kg of drum dried waxy maize and 0.5 kg of polycarbophil (Carbopol 974P) were blended until homogenous in a planetary mixer. The blend was transferred to a roller compaction machine and compacted into sheets. The resulting sheets were broken and calibrated on an oscillating sieve (mesh openings of 1 mm). The thus obtained granules were then collected and mixed with 20  
20 grams of colloidal anhydrous silica (Aerosil 200) and 200 grams of sodium stearyl fumarate until homogenous. The mixture was compressed into 100,000 flat tablets having a nominal weight of 100 mg on a Korsch compression machine equipped with 6.5 mm flat punches.

25 **Example 2**

Following the wet granulation process of example 1, two other miconazole nitrate extended release buccal tablets with the formulations given below were prepared

	1 mg tablet	5 mg tablet
miconazole nitrate (microfine)	1 mg	5 mg
30 drum dried waxy maize starch	91.8 mg	87.8 mg
Carbopol 974 P	5 mg	5 mg
colloidal anhydrous silica	0.2 mg	0.2 mg
sodium stearyl fumarate	2 mg	2 mg
ethyl alcohol *	q.s.	q.s.
35		

- \* ethanol does not appear in the end product (approximately 0.1 g ethanol is used for every gram of the dry end formulation)

**Example 3 :** Triamcinolone 1 mg extended release buccal tablet.

	microfine triamcinolone	1 mg
	drum dried waxy maize starch	91.8 mg
	sodium stearyl fumarate	2 mg
5	carbomer 974 P	5 mg
	colloidal anhydrous silica	0.2 mg

Following the small scale wet granulation method and the industrial dry compaction method described in the previous example, batches of triamcinolone 1 mg extended release buccal tablets were prepared.

**Example 4 :** Miconazole concentration in saliva from healthy volunteers after single and repeated oral administration ( $\mu\text{l/ml}$ )

Treatment	day	time	median	mean	S.D.	n
A	1	0 h	NQ	NQ	-	12
		15 min	2.5	5.6	7.5	12
		30 min	3.6	14.2	25.5	12
		45 min	20.5	20.8	20.8	12
		60 min	12.1	18.7	28.6	12
		90 min	22.4	28.1	25.5	12
		2 h	21.8	24.0	15.1	12
		3 h	33.9	35.3	20.5	12
		4 h	37.8	36.3	16.9	12
		6 h	24.7	25.3	16.0	12
		8 h	7.3	14.7	16.3	12
		12 h	NQ	NQ	-	12
	8	0 h	NQ	NQ	-	12
		15 min	NQ	4.2	6.7	12
		30 min	4.7	16.6	34.7	12
		45 min	7.2	20.4	32.9	12
		60 min	8.0	24.5	32.8	12
		90 min	13.8	31.2	34.2	12
		2 h	23.0	29.7	18.7	12
		3 h	33.9	35.7	19.5	12
		4 h	17.8	24.3	18.1	12
		6 h	14.0	15.9	16.6	12
		8 h	13.1	16.9	18.4	12
		12 h	NQ	NQ	-	12

Treatment	day	time	median	mean	S.D.	n
B	1	0 h	NQ	NQ	-	12
		5 min	41.3	60.2	53.2	12
		15 min	6.2	8.3	9.8	12
		30 min	1.5	1.9	1.8	12
		45 min	NQ	NQ	-	12
		60 min	NQ	NQ	-	12
		90 min	NQ	NQ	-	12
		2 h	NQ	NQ	-	12
		3 h	NQ	NQ	-	12
		4 h	NQ	NQ	-	12
	8	0 h	NQ	NQ	-	12
		5 min	56.9	75.9	64.6	12
		15 min	3.2	5.3	4.4	12
		30 min	1.1	1.7	2.3	12
		45 min	NQ	NQ	-	12
		60 min	NQ	NQ	-	12
		90 min	NQ	NQ	-	12
		2 h	NQ	NQ	-	12
		3 h	NQ	NQ	-	12
		4 h	NQ	NQ	-	12

Treatment A : 10 mg miconazole nitrate (improved formula of Example 1 prepared by the wet granulation process) as a bioadhesive buccal tablet o.d. for eight days.

- 5 Treatment B : 60 mg miconazole as 3 grams of an oral gel (20 mg/g) q.i.d. for eight days

NQ : not quantifiable by the GC-method (< 1.0 µg/ml)

#### Example 5

- 10 In vitro dissolution studies were performed on the improved tablet formulations of example 1. The medium was 600 ml of a mixture of 2-propanol/water (60/40) at 37°C in Apparatus 2 (USP 23, <711> Dissolution, pp. 1791-1793) (paddle, 50 rpm). In each dissolution test three tablets of 10 mg (giving a total dosis of 30 mg) miconazole nitrate were used; at regular intervals a sample of 3 ml was withdrawn from the dissolution
- 15 medium and the concentration of miconazole dissolved therein was determined by measuring the absorbance at UV wavelengths-range : 260-300 nm. In the following

tables, the amount of miconazole dissolved in the medium is expressed as (% w/w) of the total dose.

A. Tablets prepared by the wet-granulation process.

5

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	8.26	8.98	9.87	8.89	9.87	12.57	9.74
30	16.16	14.36	16.16	13.46	15.26	15.26	15.11
60	21.54	20.64	22.44	21.54	20.64	21.54	21.39
120	31.41	31.41	35.90	34.11	32.31	32.31	32.91
180	37.70	39.49	38.59	38.59	40.39	39.49	39.04
240	49.37	51.16	50.26	48.47	50.26	49.37	49.81
360	55.65	58.34	60.14	58.34	58.34	60.14	58.49
480	64.62	66.42	68.21	66.42	67.32	65.52	66.42
1440	95.14	95.14	98.73	98.73	97.83	96.04	96.94

B. Tablets prepared by the dry-compaction process

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
30	18.85	18.85	17.95	15.26	21.54	18.76	18.53
60	43.08	33.21	35.00	32.31	39.49	35.90	36.50
90	58.34	53.85	52.06	51.16	54.75	50.26	53.40
180	83.47	75.39	80.78	83.47	78.09	76.29	79.58
240	100.53	85.27	85.27	96.94	86.16	82.57	89.46

- 10 It should be noted that the above dissolution data were obtained in the unusual medium of 2-propanol/water (60/40) in order to accelerate the dissolution rate. Also, varying the compression pressure and compaction forces, yielded tablets having both slower and faster dissolution rates than these shown in the tables above. In short, the above data are provided for the purpose of showing the extended release properties of the
- 15 tablets prepared according to the present invention, but - in and of themselves - may not be taken to show any definite characteristics discernable between the wet granulation process and the dry compaction process.

**Example 6 : *In Vitro* Determination of Bioadhesion**

The bioadhesion of the tablets was evaluated according to a previously described method (S. Bouckaert, J.P. Remon, *In vitro* bioadhesion of a buccal miconazole slow-release tablet. J. Pharm. Pharmacol. 45 : 504-507 (1993). The detachment force and the work of adhesion were determined as the height and the area under the curve of the force vs extension diagram. The apparatus consisted of a tensile testing machine (type L1000R, Lloyd Instruments, Segenworth, Fareham, UK), equipped with a 20 N load cell. Porcine gingiva were obtained from a slaughter house where they were excised directly after slaughtering. The mucosa ( $\pm 100 \text{ mm}^2$ ) were stored at  $-20^\circ\text{C}$  in isotonic buffered saline pH 7.4 (2.38 g  $\text{Na}_2\text{HPO}_4 \cdot \text{H}_2\text{O}$ , 0.19 g  $\text{KH}_2\text{PO}_4$ , 8.0 g NaCl made up to 1000 ml with demineralised water).

The porcine gingival tissue was attached with cyanoacrylate glue (Loctite, Belgium) to a lower Teflon support, while the tablet was attached to an upper aluminium punch. After hydrating the mucosa with 15  $\mu\text{l}$  of the isotonic phosphate buffered saline, the tablet was fixed on the mucosa applying a force of 0.5 N for 5 min. After the initial contact, the beaker was filled with 125 ml isotonic buffered saline pH 7.4. Next, the tablet and mucosa were pulled apart at a speed of  $5 \text{ mm} \cdot \text{min}^{-1}$  until a complete rupture of the tablet-mucosa bond was obtained.

The results are reported as individual and average values ( $\pm$  SD) in the following tables.

A : 10 mg miconazole tablet (improved formula of Example 1, prepared by the wet granulation process).

B : 10 mg miconazole tablet (improved formula of Example 1, prepared by the dry compaction process).

C : 1 mg triamcinolone tablet of Example 3, prepared by the wet granulation process.

Detachment Force (N)							
	Sample 1	sample 2	sample 3	sample 4	sample 5	average	SD
A	1.219	1.086	1.068	1.353	1.126	1.1704	0.1176
B	1.285	1.466	1.581	1.373	1.524	1.4458	0.1183
C	2.08	2.684	2.998	3.068	2.265	2.619	0.437

Work of adhesion (mJ)							
	Sample 1	sample 2	sample 3	sample 4	sample 5	average	SD
A	0.092	0.115	0.131	0.208	0.122	0.1336	0.044
B	0.263	0.142	0.116	0.102	0.158	0.1562	0.0636
C	0.570	0.662	0.658	0.634	0.498	0.604	0.070

Claims

1. A bioadhesive pharmaceutical composition comprising a pharmaceutically effective amount of an active ingredient, from 80 % to 98.8 % (w/w) pre-gelatinized starch, and from 1 % to 10 % (w/w) of a hydrophilic matrix forming polymer, characterized in that the composition further comprises from 0.2 % to 5 % (w/w) alkali C<sub>16-22</sub>alkyl fumarate as a lubricant.
2. A composition according to claim 1 wherein the lubricant is micronized sodium stearyl fumarate.
3. A composition according to claim 1 comprising from 2.5 to 7.5 % (w/w) of a hydrophilic matrix forming polymer.
4. A composition according to claim 3 wherein the polymer is polyacrylic acid (carbomer), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol or a mixture thereof.
5. A composition according to claim 1 further comprising a glidant.
6. A composition according to claim 5 wherein the glidant is colloidal anhydrous silica.
7. A composition according to claim 1 comprising by weight based on the total weight  
from 0.001 % to 10 % active ingredient ;  
from 80 % to 99.8 % pre-gelatinized starch ;  
from 1 % to 10 % hydrophilic matrix forming polymer ;  
from 0.2 % to 5 % sodium stearyl fumarate ; and  
from 0 % to 1 % glidant.
8. A dosage form suitable for oral, nasal, rectal or vaginal administration which comprises a composition as claimed in any one of claims 1 to 7 and which is shaped as a tablet.
9. A buccal tablet according to claim 8 comprising by weight based on the total weight of the tablet  
10 % microfine miconazole nitrate ;

82.8 % drum dried waxy maize starch ;  
2 % sodium stearyl fumarate ;  
5 % carbomer 974 P ; and  
0.2 % colloidal anhydrous silica.

5

10. A buccal tablet according to claim 8 comprising by weight based on the total weight of the tablet

1 % microfine triamcinolone ;  
91.8 % drum dried waxy maize starch ;  
2 % sodium stearyl fumarate ;  
5 % carbomer 974 P ; and  
0.2 % colloidal anhydrous silica.

10

11. A dry process for preparing tablets or capsules comprising the steps of :

15

- intimately mixing the active ingredient, the pre-gelatinized starch and the hydrophilic matrix forming polymer in the dry state;
- compacting the thus obtained mixture into a sheet;
- breaking the sheet into a granulate;
- blending the granulate with the lubricant and optionally the glidant; and
- compressing the blend into tablets.

20

12. Products obtainable by the process according to claim 11.

13. Use of 0.2 % to 5 % (w/w) sodium stearyl fumarate as a lubricant and 80 % to 98.8 % (w/w) pre-gelatinized starch and 1 % to 10 % hydrophilic matrix forming polymer for the manufacture of a bioadhesive dosage form.

25



## INTERNATIONAL SEARCH REPORT

In\* ional Application No  
PCT/EP 96/05884A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/00 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3 554 764 A (DAVID J. YODER) 12 January 1971 see claims 1-4,7 ---	1-8,13
P,Y	EP 0 693 281 A (LILLY S.A.) 24 January 1996 see the whole document ---	1-8,13
A	EP 0 317 878 A (HOECHST AKTIENGESELLSCHAFT) 31 May 1989 see page 13; example 7 -----	1-4,13

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

27 March 1997

Date of mailing of the international search report

16.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Ventura Amat, A

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/05884

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3554764 A	12-01-71	NONE	
EP 693281 A	24-01-96	ES 2082723 A	16-03-96
		AU 2509895 A	01-02-96
		BR 9503386 A	27-02-96
		CN 1123142 A	29-05-96
		CZ 9501880 A	14-02-96
		ES 2091737 T	16-11-96
		FI 953515 A	21-01-96
		JP 8040884 A	13-02-96
		NO 952863 A	22-01-96
		PL 309721 A	22-01-96
		ZA 9506074 A	14-05-96
EP 317878 A	31-05-89	DE 3739690 A	08-06-89
		AU 2581888 A	25-05-89
		CN 1028962 B	21-06-95
		DE 3869919 A	14-05-92
		DK 168423 B	28-03-94
		FI 93693 B	15-02-95
		IE 61173 B	05-10-94
		JP 1165596 A	29-06-89
		JP 7068140 B	26-07-95
		NO 176550 B	16-01-95
		US 5442008 A	15-08-95
		US 5151433 A	29-09-92